Viatris Inc (VTRS)vscbdMD Inc (YCBD)
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
YCBD
cbdMD Inc
$0.77
+1.06%
HEALTHCARE · Cap: $6.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 75059% more annual revenue ($14.30B vs $19.03M). YCBD leads profitability with a -8.0% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
VTRS
Buy50
out of 100
Grade: C-
YCBD
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for VTRS.
Margin of Safety
+78.3%
Fair Value
$3.47
Current Price
$0.77
$2.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -33.1% — below average capital efficiency
Revenue declined 11.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bull Case : YCBD
The strongest argument for YCBD centers on P/E Ratio, Price/Book.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Bear Case : YCBD
The primary concerns for YCBD are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
YCBD carries more volatility with a beta of 2.21 — expect wider price swings.
VTRS is growing revenue faster at 5.0% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTRS scores higher overall (50/100 vs 31/100). YCBD offers better value entry with a 78.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →cbdMD Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company is headquartered in Charlotte, North Carolina.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?